6-K ·Filed May 18, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001575872-26-000339
Notable filing: 6-K
Actionable Insight • Neutral

This is a standard non-deal roadshow schedule with no material information. No trading action warranted. Monitor for any subsequent 6-K filings that may contain earnings results or business updates from these meetings.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
RDY ▼ -8.90% at T+60d
NEUTRAL call ✗ call lost -8.90% · α vs SPY -13.75% · entry $13.60 → $12.39
Entry anchored
May 18, 2026
via day open
T+1d
-1.10%
call -1.10% · α -0.45%
$13.45
settled 5mo ago
T+5d
+1.10%
call +1.10% · α -0.52%
$13.75
settled 4mo ago
T+20d
-2.21%
call -2.21% · α -3.79%
$13.30
settled 4mo ago
T+60d
-8.90%
call -8.90% · α -13.75%
$12.39
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May 20 to June 3, 2026, hosted by Elara Capital, Bank of America, Nomura, and Investec across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton. This is a routine disclosure of non-deal roadshow activity with no material financial information, guidance, or operational updates.

Key Facts

  • Management will participate in investor meetings from May 20 to June 3, 2026
  • Meetings hosted by Elara Capital, Bank of America, Nomura, and Investec
  • All meetings are in-person group meetings across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton
  • No financial results, guidance, or material business updates were disclosed

Financial Impact

No financial figures disclosed — routine investor relations activity with no quantifiable impact

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000339
Document: 0001575872-26-000339-index.html0001575872-26-000339
Document: 0001575872-26-000339.txt0001575872-26-000339
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access